Profile data is unavailable for this security.
About the company
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
- Revenue in USD (TTM)0.00
- Net income in USD-57.67m
- Incorporated2006
- Employees14.00
- LocationSagimet Biosciences Inc155 BOVET RD., SUITE 303SAN MATEO 94402United StatesUSA
- Phone+1 (650) 561-8600
- Fax+1 (302) 730-1370
- Websitehttps://sagimet.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals Inc | 0.00 | -133.35m | 152.04m | 61.00 | -- | 1.63 | -- | -- | -2.21 | -2.21 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -65.18 | -33.77 | -72.61 | -35.61 | -- | -- | -- | -21,273.47 | -- | -- | 0.2475 | -- | -- | -- | -95.39 | -- | -- | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 152.96m | 140.00 | -- | 0.8587 | -- | 1.35 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| ProQR Therapeutics NV | 19.08m | -50.52m | 153.80m | 166.00 | -- | 2.32 | -- | 8.06 | -0.4858 | -0.4858 | 0.1837 | 0.6288 | 0.139 | -- | 9.70 | 114,910.10 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -10.27m | 160.06m | 31.00 | -- | 3.42 | -- | -- | -0.0993 | -0.0993 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -65.28 | -46.29 | -73.32 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 161.78m | 6.00 | -- | 3.86 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 164.56m | 14.00 | -- | 1.38 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| MDxHealth SA | 103.07m | -31.43m | 168.29m | 312.00 | -- | -- | -- | 1.63 | -0.7275 | -0.7275 | 2.21 | -0.1669 | 0.6614 | 7.00 | 6.20 | 330,349.30 | -20.17 | -40.27 | -29.24 | -50.75 | 64.48 | 57.38 | -30.50 | -76.84 | 1.02 | -0.8112 | 1.10 | -- | 28.29 | 50.19 | 11.67 | -- | 96.87 | -- |
| Tharimmune Inc | 0.00 | -10.32m | 169.03m | 2.00 | -- | 5.25 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Cartesian Therapeutics Inc | 1.93m | -50.61m | 169.54m | 66.00 | -- | -- | -- | 87.98 | -1.97 | -1.97 | 0.0743 | -1.38 | 0.0047 | -- | 0.6943 | 29,196.97 | -11.59 | -33.50 | -12.10 | -45.25 | -- | -- | -2,489.83 | -128.46 | -- | -- | -- | -- | 49.64 | 42.27 | 69.90 | -- | 186.63 | -- |
| Editas Medicine Inc | 46.38m | -199.84m | 171.81m | 246.00 | -- | 12.20 | -- | 3.70 | -2.38 | -2.38 | 0.5454 | 0.1443 | 0.1753 | -- | 11.24 | 188,548.80 | -75.51 | -34.19 | -101.13 | -38.43 | -- | -- | -430.84 | -373.02 | -- | -- | 0.8145 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
| Zentalis Pharmaceuticals Inc | 26.87m | -149.32m | 172.68m | 166.00 | -- | 0.6828 | -- | 6.43 | -2.08 | -2.08 | 0.3743 | 3.50 | 0.0691 | -- | -- | 161,837.30 | -38.39 | -43.59 | -43.54 | -49.56 | -- | -- | -555.80 | -1,402.74 | -- | -- | 0.00 | -- | -- | -- | 43.24 | -- | -8.89 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 174.99m | 8.00 | -- | 17.95 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
| Galectin Therapeutics Inc | 0.00 | -37.44m | 177.94m | 15.00 | -- | -- | -- | -- | -0.5913 | -0.5913 | 0.00 | -1.92 | 0.00 | -- | -- | 0.00 | -178.33 | -117.54 | -- | -197.34 | -- | -- | -- | -- | -- | -3.57 | -- | -- | -- | -- | -5.35 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Woodline Partners LPas of 30 Sep 2025 | 1.50m | 4.84% |
| Affinity Asset Advisors LLCas of 31 Dec 2025 | 1.15m | 3.70% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.08m | 3.50% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 953.00k | 3.07% |
| Marshall Wace LLPas of 31 Dec 2025 | 780.45k | 2.52% |
| Millennium Management LLCas of 30 Sep 2025 | 776.38k | 2.50% |
| HHLR Advisors Ltd.as of 30 Sep 2025 | 724.80k | 2.34% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 701.24k | 2.26% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 566.55k | 1.83% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2025 | 523.77k | 1.69% |
